EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both

Amy Mottl iD, Charlie Scott iD, Jennifer B Green iD, Hiddo J L Heerspink iD, Johannes F E Mann iD, Janet B McGill iD, Masaomi Nangaku iD, Julio Rosenstock iD, Peter Rossing iD, Li Li, Na Li, Muthiah Vaduganathan iD und 2 weitere

Journal of the American Society of Nephrology · 2026-04 · 37 (4) · 764-776

DOI: 10.1681/asn.0000000928 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 06.11.2025. Verfasst von Amy Mottl und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina School of Medicine, Chapel Hill, North Carolina. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Albuminuria, Creatinine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points We assessed whether baseline urine albumin-creatinine ratio (UACR) and eGFR modify treatment effects on UACR reduction and safety in the CONFIDENCE trial. Higher baseline eGFR or UACR, age, female sex, and atherosclerotic cardiovascular disease were associated with greater albuminuria lowering at 6 months (180 days). Treatment effects on efficacy and safety were consistent, with no significant heterogeneity across baseline UACR or eGFR groups.

Background

In the CONFIDENCE trial, simultaneous initiation of finerenone (10 or 20 mg) and empagliflozin (10 mg) was superior to either monotherapy in reducing albuminuria at 180 days in participants with type 2 diabetes and CKD. In this analysis, we evaluated whether baseline urine albumin-creatinine ratio (UACR) and eGFR were associated with the magnitude of UACR reduction, and whether baseline UACR and eGFR modify the effect of combination treatment.

Methods

In this post hoc analysis of the CONFIDENCE trial ( n =796), linear mixed-effects models were used to evaluate the effects of baseline UACR and eGFR on the change in UACR from baseline using subgroups on the basis of clinically relevant thresholds of UACR (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesBenzhydryl CompoundsAlbuminuriaCreatinineSodium-Glucose Transporter 2 InhibitorsNaphthyridinesDiabetes Mellitus, Type 2Renal Insufficiency, ChronicDiabetic NephropathiesHumansFemaleMaleMiddle AgedGlomerular Filtration RateAgedDrug Therapy, Combination

Stichwörter der Autor:innen

CKDGFRalbuminuriaclinical trial

Substanzen

empagliflozinGlucosidesBenzhydryl CompoundsCreatininefinerenoneSodium-Glucose Transporter 2 InhibitorsNaphthyridines

Autor:innen und Institutionen

  • University of North Carolina School of Medicine, Chapel Hill, North Carolina.
  • Bayer Healthcare Inc., Whippany, New Jersey.
  • Duke University School of Medicine, Durham, North Carolina.
  • University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.
  • KfH Kidney Centre Munich and Friedrich Alexander University, Erlangen, Germany.
  • Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, St. Louis, Missouri.

ORCID-Profile: Amy Mottl, Charlie Scott, Jennifer B Green, Hiddo J L Heerspink, Johannes F E Mann, Janet B McGill, Masaomi Nangaku, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Rajiv Agarwal

Förderung

  • Bayer

Zitieren

APA

Mottl, A., Scott, C., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Nangaku, M., Rosenstock, J., Rossing, P., Li, L., Li, N., Vaduganathan, M., Agarwal, R., & CONFIDENCE Trial Investigators (2026). Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both. Journal of the American Society of Nephrology, 37(4), 764-776. https://doi.org/10.1681/asn.0000000928

Vancouver

Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, et al. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both. Journal of the American Society of Nephrology. 2026;37(4):764-776. doi:10.1681/asn.0000000928

BibTeX
@article{Mottl2026,
  author = {Mottl, Amy and Scott, Charlie and Green, Jennifer B and Heerspink, Hiddo J L and Mann, Johannes F E and McGill, Janet B and Nangaku, Masaomi and Rosenstock, Julio and Rossing, Peter and Li, Li and Li, Na and Vaduganathan, Muthiah and Agarwal, Rajiv and CONFIDENCE Trial Investigators, CONFIDENCE Trial Investigators},
  title = {Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  volume = {37},
  number = {4},
  pages = {764--776},
  doi = {10.1681/asn.0000000928}
}
Kostenlos starten →